Department of Cardiology, Heart Center, Chongqing Three Gorges Central Hospital, Affiliated Three Gorges Hospital of Chongqing University, Chongqing, China.
Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.
PLoS One. 2020 Apr 29;15(4):e0231687. doi: 10.1371/journal.pone.0231687. eCollection 2020.
Heart-fatty acid binding protein (HFABP) has been recognized as a highly heart-specific marker. However, it is currently unknown that its HFABP is also closely related to the severity of COVID-19.
We retrospectively screened 46 patients who met our inclusion criteria within 4 weeks. They were tested for HFABP after the diagnosis of COVID-19, and monitored for HFABP during their hospital stay. We tracked the patients during their hospital stay to determine if they had severe COVID-19 or mild-to-severe transition features. We calculated the chi-square test values found for HFABP to predict the correlation between HFABP levels and the severity of the COVID-19.
Of these 46 cases, 16 cases with confirmed COVID-19 were tested for HFABP> 7 ng / mL upon admission; among them, 14 cases were diagnosed with severe COVID-19 within the hospitalization. The Odds ratio of the measured HFABP elevation was 6.81(95% confidence interval [CI] 5.23-8.40), and 3 patients with severe COVID-19 progressed in 5 patients with mild HFABP> 7 ng/mL.
These data indicate that the elevation of HFABP is closely related to the severity of COVID-19 in the patients, and the elevated HFABP may cause rapid development of patients with mild COVID-19 into severe COVID-19. But serum HFABP negative maybe make patients with mild COVID-19 safer, the current data show no effect on the all-cause mortality.
Our study has been registered with the Chinese Clinical Trial Registry, the registration number: ChiCTR2000029829.
心脏脂肪酸结合蛋白（HFABP）已被认为是一种高度心脏特异性标志物。然而，目前尚不清楚其 HFABP 也与 COVID-19 的严重程度密切相关。
我们回顾性筛选了 46 名符合纳入标准的患者，他们在 COVID-19 诊断后检测 HFABP，并在住院期间监测 HFABP。我们在住院期间跟踪患者，以确定他们是否患有严重 COVID-19 或轻度至重度过渡期特征。我们计算了 HFABP 的卡方检验值，以预测 HFABP 水平与 COVID-19 严重程度之间的相关性。
在这 46 例患者中，有 16 例确诊 COVID-19 的患者入院时检测到 HFABP>7ng/ml；其中，14 例在住院期间被诊断为严重 COVID-19。HFABP 升高的比值比为 6.81（95%置信区间 [CI] 5.23-8.40），3 例 HFABP 升高的严重 COVID-19患者中有 5 例进展为严重 COVID-19。
这些数据表明，HFABP 的升高与 COVID-19 患者的严重程度密切相关，升高的 HFABP 可能导致轻度 COVID-19 患者迅速发展为严重 COVID-19。但是血清 HFABP 阴性可能使轻度 COVID-19 患者更安全，目前的数据显示对全因死亡率没有影响。
我们的研究已在中国临床试验注册中心注册，注册号：ChiCTR2000029829。
